Datapoint: Yescarta Scores Follicular Lymphoma Nod

The FDA on March 5 approved Gilead Sciences’ Yescarta for the treatment of relapsed or refractory follicular lymphoma in patients that have not responded to at least two prior treatments, a feat unmatched by its CAR-T rivals Kymriah and Breyanzi. Under the medical benefit, Yescarta is covered for 32% of all insured lives for the treatment of diffuse large B-cell lymphoma. A further 41% of covered lives have medical benefit access to Yescarta with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/10/21

0

0

0 Comments

0

0

• Datapoint